0000000000395567
AUTHOR
B. Kang
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
Background: A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy. Materials and methods: We carried out a retrospective analysis of prospectively collected data from consecutive patients with non-viral advanced HCC, treated with atezolizumab plus bevacizumab, lenvatinib, or sorafenib, in 36 centers in 4 countries (Italy, Japan, Republic of Korea, and UK). The primary endpoint was overall survival (OS) with atezolizumab plus bevacizumab versus lenvatinib. Secondary endpoints were progression-free survival (PFS) with atezolizumab plus bevacizumab versus lenvatinib, and OS and PFS with atezolizumab plus bevacizumab versus soraf…
Mesonic and Non-Mesonic Weak Decay of Hypernuclei with FINUDA
Abstract The FINUDA experiment performed a systematic study of both mesonic and non-mesonic weak decay of p - shell Λ-hypernuclei. Recent results on the mesonic decay rates and the non-mesonic decay ratios are illustrated and briefly discussed.
New results on mesonic weak decay of p-shell Lambda-hypernuclei
The FINUDA experiment performed a systematic study of the charged mesonic weak decay channel of $p$-shell $\Lambda$-hypernuclei. Negatively charged pion spectra from mesonic decay were measured with magnetic analysis for the first time for ${^{7}_{\Lambda}Li}$, ${^{9}_{\Lambda}Be}$, ${^{11}_{\Lambda}B}$ and ${^{15}_{\Lambda}N}$. The shape of the $\pi^{-}$ spectra was interpreted through a comparison with pion distorted wave calculations that take into account the structure of both hypernucleus and daughter nucleus. Branching ratios $\Gamma_{\pi^{-}}/\Gamma_{tot}$ were derived from the measured spectra and converted to $\pi^{-}$ decay rates $\Gamma_{\pi^{-}}$ by means of known or extrapolate…